Guided Therapeutics (GTHP) Depreciation & Amortization (CF) (2011 - 2026)

Guided Therapeutics has reported Depreciation & Amortization (CF) for 13 years, with the latest figure at $3000.0 in Q4 2025.

• Quarterly Depreciation & Amortization (CF) rose 50.0% year-over-year to $3000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $10000.0 (up 11.11% YoY) and the FY2025 annual result came in at $10000.0, up 11.11% from the prior year.
• Depreciation & Amortization (CF) grew to $3000.0 in Q4 2025 per GTHP's latest filing, from $2000.0 in the prior quarter.
• Over five years, Depreciation & Amortization (CF) peaked at $3000.0 in Q4 2022 and troughed at $1000.0 in Q3 2022.
• A 4-year average of $2285.7 and a median of $2000.0 in 2023 frame the typical range for Depreciation & Amortization (CF).
• The widest YoY moves for Depreciation & Amortization (CF): up 100.0% in 2023, down 33.33% in 2023.
• Over 4 years, Depreciation & Amortization (CF) stood at $3000.0 in 2022, then plunged by 33.33% to $2000.0 in 2023, then changed by 0.0% to $2000.0 in 2024, then jumped by 50.0% to $3000.0 in 2025.
• According to Business Quant data, Depreciation & Amortization (CF) over the past three periods registered $3000.0, $2000.0, and $3000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.